Development · 22 Aug 2026
DRREDDY, full dossier1 publisher has reported this development. Each act of reporting is below, cited.
The Delhi High Court ruled that Dr. Reddy's Labs' Daplo trademark is deceptively similar to Razenta Pharmaceuticals' Daplogin trademark and ordered the trademark registrar to cancel Razenta's Daplogin trademark within six weeks.
The Delhi High Court ordered the trademark registrar to cancel Razenta Pharmaceuticals' Daplogin trademark within six weeks, finding it deceptively similar to Dr. Reddy's Labs' Daplo trademark for identical Type-2 diabetes medications.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.